Market Overview:
The global JAK inhibitor drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of rheumatoid arthritis, polycythemia vera, and myelofibrosis. Additionally, the increasing demand for targeted therapies is also contributing to the growth of this market. The global JAK inhibitor drug market can be segmented on the basis of type into tofacitinib, ruxolitinib, and baricitinib. On the basis of application, this market can be segmented into rheumatoid arthritis (RA), polycythemia vera (PCV), and myelofibrosis (MF). The global JAK inhibitor drug market can be further divided on a regional basis into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
A JAK inhibitor is a type of drug that blocks the activity of the Janus kinase (JAK) enzyme. This enzyme is involved in the transmission of signals from outside a cell to its interior, and JAK inhibitors can be used to treat diseases that are caused by abnormal signaling pathways.
Tofacitinib:
Tofacitinib is a JAK3 inhibitor. It works by decreasing the activity of Janus kinase 3, which is responsible for signaling pathway and leads to cell growth inhibition. Tofacitinib was approved by the FDA in March 2017 as second-line therapy for non-small cell lung cancer (NSCLC) after chemotherapy or radiation treatment.
Ruxolitinib:
Ruxolitinib (JAK1 inhibitor) is a drug that is under development by Janssen Pharmaceutical, LLC. for the treatment of multiple myeloma and non-small cell lung cancer. Ruxolitinib was granted breakthrough therapy approval by the U.S.
Application Insights:
Rheumatoid arthritis (RA) was the most prominent application segment of the global JAK inhibitor drug market in 2017. The disease is a chronic one and affects mostly adults, leading to disability and social isolation. As per U.S. Centers for Disease Control and Prevention (CDC), around 1 in 4 people aged between 18 to 64 have some form of arthritis or rheumatic condition, globally speaking, which amounts to over 300 million individuals as of 2016.
The polycythemia Vera (PV) segment held the second-largest share owing to increasing incidence rates of this blood disorder across all age groups; affecting mainly young adult males with an average annual incidence rate ranging from 10% - 40%. PV is a common term used for multiple myeloma or monoclonal gammopathy of undetermined significance (MNGOS).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and high healthcare expenditure are some of the factors responsible for its growth. In addition, increasing prevalence of rheumatoid arthritis is expected to further drive this market over the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the forecast period owing to rising disposable income and improving economic conditions in emerging countries such as China and India.
Growth Factors:
- Increasing prevalence of autoimmune diseases: The global autoimmune diseases market is expected to grow at a CAGR of 7.5% from 2016 to 2021, owing to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. This is expected to drive the demand for JAK inhibitors in the coming years.
- Rising awareness about JAK inhibitors: There is a growing awareness among physicians and patients about the benefits of JAK inhibitors in treating various autoimmune diseases. This is likely to boost the demand for these drugs in the coming years.
- Growing pipeline of novel JAK inhibitors: The pharmaceutical companies are investing heavily in R&D activities for developing novel JAK inhibitors with better efficacy and safety profiles than existing drugs in this class. This is likely to fuel growth prospects for this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
JAK inhibitor Drug Market Research Report
By Type
Tofacitinib, Ruxolitinib, Baricitinib
By Application
Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF)
By Companies
Pfizer, Incyte, Novartis, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global JAK inhibitor Drug Market Report Segments:
The global JAK inhibitor Drug market is segmented on the basis of:
Types
Tofacitinib, Ruxolitinib, Baricitinib
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF)
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Incyte
- Novartis
- Eli Lilly
Highlights of The JAK inhibitor Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tofacitinib
- Ruxolitinib
- Baricitinib
- By Application:
- Rheumatoid Arthritis (RA)
- Polycythemia Vera (PCV)
- Myelofibrosis (MF)
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the JAK inhibitor Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A Jak inhibitor is a type of medication that blocks the activity of the Jak protein. This protein helps cells to move and divide. By blocking the activity of this protein, jak inhibitors can help to slow down or stop cancer growth.
Some of the key players operating in the jak inhibitor drug market are Pfizer, Incyte, Novartis, Eli Lilly.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 JAK inhibitor Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 JAK inhibitor Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 JAK inhibitor Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the JAK inhibitor Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global JAK inhibitor Drug Market Size & Forecast, 2020-2028
4.5.1 JAK inhibitor Drug Market Size and Y-o-Y Growth
4.5.2 JAK inhibitor Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tofacitinib
5.2.2 Ruxolitinib
5.2.3 Baricitinib
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Rheumatoid Arthritis (RA)
6.2.2 Polycythemia Vera (PCV)
6.2.3 Myelofibrosis (MF)
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global JAK inhibitor Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 JAK inhibitor Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tofacitinib
9.6.2 Ruxolitinib
9.6.3 Baricitinib
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Rheumatoid Arthritis (RA)
9.10.2 Polycythemia Vera (PCV)
9.10.3 Myelofibrosis (MF)
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tofacitinib
10.6.2 Ruxolitinib
10.6.3 Baricitinib
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Rheumatoid Arthritis (RA)
10.10.2 Polycythemia Vera (PCV)
10.10.3 Myelofibrosis (MF)
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tofacitinib
11.6.2 Ruxolitinib
11.6.3 Baricitinib
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Rheumatoid Arthritis (RA)
11.10.2 Polycythemia Vera (PCV)
11.10.3 Myelofibrosis (MF)
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tofacitinib
12.6.2 Ruxolitinib
12.6.3 Baricitinib
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Rheumatoid Arthritis (RA)
12.10.2 Polycythemia Vera (PCV)
12.10.3 Myelofibrosis (MF)
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tofacitinib
13.6.2 Ruxolitinib
13.6.3 Baricitinib
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Rheumatoid Arthritis (RA)
13.10.2 Polycythemia Vera (PCV)
13.10.3 Myelofibrosis (MF)
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 JAK inhibitor Drug Market: Competitive Dashboard
14.2 Global JAK inhibitor Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Incyte
14.3.3 Novartis
14.3.4 Eli Lilly
